StemCell Therapy

The competition for Maryland's stem cell research grants will be stiffer than ever as applications flood in next month, forcing officials to be more selective even as scientists worry that the state's fiscal problems and a new administration in Annapolis may mean smaller budgets in the future.

The Maryland Stem Cell Research Commission received a record 240 letters declaring intent to apply for $10.4 million in grants, officials said this month. While the majority came from researchers, more than a dozen came from startups and other companies and half a dozen for work testing therapies on humans proof that the 8-year-old program is boosting the state's biotechnology industry, officials said.

But that also means the state likely will reject more applications for the grants than in previous years. And with no funding promises from Gov.-elect Larry Hogan and state budget cuts looming, researchers worry there will be less to go around in 2016 and beyond.

The uncertainty comes just as advancements in stem cell science are making more research possible, threatening progress in Maryland even as other states surge forward, researchers said.

"In California, they have $3 billion. Here, we have $10 million a year. It is very hard," said Ricardo Feldman, an associate professor of microbiology and immunology at the University of Maryland School of Medicine. "Not all of us who have exciting results are going to get it, and some of us who do not get funding will not be able to continue what we started, and that will be very sad."

At an annual symposium on state-funded stem cell research this month, state stem cell commission officials said they received letters of intent from a record 16 companies as well as seven proposals for clinical work and 144 proposals for "translational" work research that aims to turn basic science into viable therapies. Applications are due Jan. 15.

Historically, the awards have gone more for university research and projects that are still at least a few steps away from being used in hospitals, but the surge in commercial and clinical work is a product of the state's long-term commitment to the grants, said Dan Gincel, the stem cell research fund's executive director.

The grants help research projects advance to a stage where they can attract backers like drug companies or other for-profit investors, who are more discriminating in the projects they support since many end up going nowhere.

"A long-term commitment is extra important for something so high-risk," Gincel said. "You gain trust that this is going somewhere."

There aren't many investors for researchers to turn to early on, said Jennifer Elisseeff, a professor of biomedical engineering at the Johns Hopkins University who has been part of teams receiving $920,000 in state grants over the past two years. She and colleagues are exploring how to stimulate stem cells to regrow tissues, a project she called "kind of basic science-y but also very applied."

Read more here:
Record competition for stem cell grants means tough choices for state officials

The Newport Beach Stem Cell Treatment Center provides cutting-edge care for patients with a wide variety of degenerative disorders using adult stem cell regenerative therapy. Our highly trained physicians and medical team are focused on providing you with the most innovative techniques and advanced procedures for harvesting and deploying adult stem cells from your own fat. We are also committed to clinical research and the advancement of regenerative medicine.

We are dedicated to the principles of personalized patient care and individualized attention. Our plastic surgeon, a pioneer in liposuction, and topnotch team of registered nurses and technicians are experienced in harvesting and deploying adult stem stems. In addition, our comfortable in-office surgery center is fully accredited by the Institute for Medical Quality, a division of the California Medical Association. Our goal is to provide you with the best possible care in a friendly and professional atmosphere.

Fat is the bodys most abundant repository of adult stem cells, containing thousands of times more stem cells than bone marrow. New technologies at the Newport Beach Stem Cell Treatment Center make it possible for us to remove a few ounces of a patients fat through liposuction, separate out the stem cells in a special process that yields extremely high numbers of viable cells, and return them back into the patients body via IV or injection. Performed in a physicians office under sedation and local anesthesia and using a sterile closed system technology (so the cells never come into contact with the environment), there is minimal discomfort and risk of infection. And because the cells come from the patients own body, there is no risk of rejection or disease transmission.

Posted by Mark Baldwin on Nov 28, 2012 in Cardiac / Pulmonary

Posted by Mark Baldwin on Nov 28, 2012 in Cardiac / Pulmonary

Posted by Mark Baldwin on Nov 28, 2012 in Cardiac / Pulmonary

Posted by Mark Baldwin on Nov 28, 2012 in Cardiac / Pulmonary

Read more from the original source:
Newport Beach Stem Cell Treatment Center - Stem Cell ...

SWS - Episode 3 - Stem Cell Biology
You #39;ve heard about brain cells. You #39;ve heard about skin cells. You #39;ve heard about stem cells. Here #39;s some stem cells. Here #39;s the link to a video I made explaining the basics of stem cell biology....

By: ScienceWhileSciencing

Read more here:
SWS - Episode 3 - Stem Cell Biology - Video

Knee Cartilage Repair With Tissue Engineered Scaffold To Hold Patient #39;s Own Stem Cells
Cartilage in the knee can get damaged by sporting injuries (different from wear and tear in the older patient). These injuries respond very well to stem cell procedures when coupled with tissue...

By: Orthopaedic Clinic, Singapore - Limb Salvage and Revision Arthroplasty Surgery Pte Ltd

The rest is here:
Knee Cartilage Repair With Tissue Engineered Scaffold To Hold Patient's Own Stem Cells - Video

Torn Knee Meniscus
http://www.kneestemcells.com Dennis Lox, M.D. is definitely an expert in Leg Stem Cell Treatments by providing Joint Stem Cell Therapy for those who seek an alternative for that in the past #39;s...

By: Powetis Ivanov

More here:
Torn Knee Meniscus - Video

FAT STEM CELL COMBINED/ Stem Cell Therapy
Adipose-Derived Stem Cells derived from the patients own fat provides a rich source of adult mesenchymal stem cells as demonstrated by Dr. Hong in this sessi...

By: Kab S. Hong M.D.

Continued here:
FAT STEM CELL COMBINED/ Stem Cell Therapy - Video

Dominique Friend doesn't look like she's sick. But the Lansdowne resident often deals with bouts of pain so severe she ends up in the hospital for weeks.

Friend, 44, was born with sickle cell disease, an inherited blood disorder that affects an estimated 90,000 to 100,000 in the U.S., according to Centers for Disease Control and Prevention information.

Her autobiography "Sickle" was released by Tate Publishing on Dec. 9 in a second edition, after she self-published the book in 2009.

In the book, she tells of her struggle with the debilitating disease. Friend said she shared her personal account to raise awareness about the disease, which predominantly affects African-Americans. It is also found in those of Hispanic and Mediterranean descent, according to CDC information.

Friend said for as long as she can recall, she has dealt with painful episodes that are characteristic of sickle cell disease.

Pain develops when sickle-shaped red blood cells, that should be round like a doughnut, block the blood flow to the chest, joints and other parts of the body, Friend explained. It can last for a few hours to a few weeks and such episodes are called "crises," she said.

"I would take the pain of childbirth over a sickle cell crisis any day," said Friend, who has three children, two stepdaughters and two granddaughters.

She has been married to Michael Friend for 18 years.

The painful disease can disrupt learning for children and make it difficult for adults to work, said Dr. Sophie Lanzkron, an assistant professor of medicine and oncology at Johns Hopkins University School of Medicine.

A bone marrow transplant or stem cell transplant is the only cure, according to the CDC website.

Continue reading here:
Lansdowne author raises awareness about sickle cell disease

Bone Marrow Stem Cell Therapy / Stem Cell Prolotherapy
Stem Cell Prolotherapy is a procedure in which adult mesenchymal stem cells are transplanted directly into the damaged tissue or injury and promotes healing. Stem cells are the repairmen...

By: Kab S. Hong M.D.

Link:
Bone Marrow Stem Cell Therapy / Stem Cell Prolotherapy - Video

Source: ISNA

Iran inaugurated the cell therapy and regenerative medicine center affiliated to the country's Red Crescent Society in a ceremony attended by Iranian Vice President for Science and Technology Affairs Sorena Sattari.

"Stem cells are of great importance for the future. If we want to describe the modern medicine, we should say that one of its important bases is stem cell," he said.

He also said scientific projects take 10-15 years to turn into trade products.

In 2013, Iran hosted an international congress on stem cell and biomedicine attended by representatives of major medical research groups mostly from China, India, Italy and US and Iran have taken part in the two-day event and was organized by Iran's Royan institute.

The congress aimed to bring together the researchers and practitioners from all over the world in stem cells and reproductive biomedicine to stimulate and promote research in this area.

Stem cell research is one of the most promising research areas in modern biomedicine. However, due to moral and ethical debates, it remains a controversial issue in many regions of the world.

Stem cells have been shown to have significant capability to develop into a plethora of different cell types and work as a repair system to replenish cells with specialized functions.

Due to the efforts of Iranian scientists, doctors, engineers and researchers, Iran has advanced tremendously in the fields of stem cell research, medicine, nanotechnology, biotechnology and aerospace engineering.

More here:
Iran opens cell therapy center

Jeunesse@Global LUMINECE products presentation ENG
Information all about LUMINESCE Jeunesse Global #39;s Luminesce contains the same biological language that stem cells use to repair cells and rejuvenate tissue and skin. Jeunesse Global ...

By: beauty connection

Read more here:
Jeunesse@Global LUMINECE products presentation ENG - Video

Stem Cells: Tools for Human Genetics and Heart Regeneration
Department of Medicine Grand Rounds presentation by Dr. Charles Murry, professor, Department of Pathology, Bioengineering and Medicine/Cardiology; Director, Center for Cardiovascular Biology;...

By: UWDeptMedicine

More:
Stem Cells: Tools for Human Genetics and Heart Regeneration - Video

Boston, MA (PRWEB) December 23, 2014

Earlier this year in a June 24 international conference presentation, Dr. James L. Sherley, director of the Adult Stem Cell Technology Center, LLC (ASCTC) focused attention on an often overlooked and under appreciated unique property of adult tissue stem cells. His title Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the Past, Important for the Future, embodied the essence of his message to congress participants. He gave the address at the 4th World Congress on Cell Science and Stem Cell Research in Valencia, Spain.

The international congress was organized by the Omics Group as a part of its mission to foster the dissemination of leading discoveries and advances in life sciences research. Their posting this month of the slides from Dr. Sherley's June 24 keynote address now provides worldwide open access to life sciences investigators - stem cell biologists in particular - of the concepts that he emphasized.

In a 2008 publication [Breast Disease 29, 37-46, 2008], Sherley coined the new term distributed stem cells (DSCs) as a biology-based name for all natural tissue stem cells that are not embryonic in origin. Adult stem cells are included under the DSC heading. DSCs do not make every cell in the body. Their nature is to produce only a limited tissue-specific or organ-specific distribution of the total possible mature cell types. So, for example, liver DSCs make mature liver cells, but not mature cells found in other organs like the lungs.

Since 2001 and the start of "the stem cell debate," Sherley has insisted that only DSCs can be effective for developing new cellular therapies. In his keynote address, he explained to attendees why the counterparts of DSCs human embryonic stem cells (hESCs) and more recently developed induced pluripotent stem cells (iPSCs) could not.

Though many stem cell scientists recognize and acknowledge the genetic defects, incomplete differentiation, and tumor formation problems of hESCs and iPSCs - which their proponents suggest can be solved - few appreciate their greater problem, which cannot be solved. Unlike DSCs, hESCs and iPSCs lack the property of asymmetric self-renewal.

Sherleys main message is that asymmetric self-renewal, which is the gnomonic for DSCs the very property that defines DSCs is essential for effective cellular therapies. Asymmetric self-renewal means that DSCs can actively multiply with simultaneous reproduction of themselves and production of mature cells. This ability allows DSCs to replenish mature cells, which are continuously lost from tissues and organs, but not lose their genetic blueprint required for tissue and organ renewal and repair.

The asymmetric self-renewal of DSCs is a crucial consideration for all aspects of their study and use. Sherley argues that overlooking it is holding back progress in regenerative medicine. Asymmetric self-renewal is the factor that limits the production of DSCs; but it is so unique to them that it can also be used to identify DSCs, which are notorious for being elusive. The ASCTCs patented technologies for producing and counting DSCs for research and clinical development are grounded in the companys special research and bioengineering expertise for DSC asymmetric self-renewal.

Asymmetric self-renewal may even play a role in the efficient production of iPSCs. At the end of his address, Sherley announced the approval of a new ASCTC patent. The patent covers the invention of a method to make iPSCs from DSCs that were produced by regulating their asymmetric self-renewal (U.S. Patent and Trademark Office No. 8,759,098).

The ASCTC anticipates that despite the new technologys origin in DSC research, it will advance human disease research based on iPSCs. Although iPSCs are not suitable for cell therapy applications, they are uniquely able to provide disease research models for hard to obtain cell types found in patients (e.g., brain cells from autism patients, cardiac cells from heart disease patients).

Continued here:
Adult Stem Cell Technology Center, LLCs Director Sherley's Address on Whats Holding Back Regenerative Medicine ...

(New York City) A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life-threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.

Patients with fatal blood cancers like leukemia often require allogenic stem cell SCT to survive. Donor stem cells are transplanted to a recipient, but not without the risk of developing GVHD, a life-threatening complication and major cause of death after SCT. The disease, which can be mild to severe, occurs when the transplanted donor cells (known as the graft) attack the patient (referred to as the host). Symptom severity, however, does not accurately define how patients will respond to treatment and patients are often treated alike with high-dose steroids. Although SCT cures cancer in 50 percent of the patients, 25 percent die from relapsed cancer and there remaining go into remission but later succumb to effects of GVHD.

"High dose steroids is the only proven treatment for GVHD," said James L. M. Ferrara, MD, DSc, Ward-Coleman Chair in Cancer Medicine Professor at the Icahn School of Medicine at Mount Sinai, Director of Hematologic Malignancies Translational Research Center at Tisch Cancer Institute at Mount Sinai. "Those with low-risk GVHD are often over-treated and face significant side-effects from treatment. Patients with high risk GVHD are undertreated and the GVHD progresses, often with fatal consequences. Our goal is to provide the right treatment for each patient. We hope to identify those patients at higher risk and design an aggressive intervention while tailoring a less-aggressive approach for those with low-risk."

Dr. Ferrara, along with a multi-center team of researchers, developed and tested this new scoring system using almost 500 patient blood samples with newly diagnosed GVHD in varying grades from two different centers. They used three validated biomarkers TNFR1, ST2 and Reg3 to create an algorithm that calculated the probability of non-relapse mortality (usually caused by GVHD) that provided three distinct risk scores to predict the patient's response to GVHD treatment.

The acid test was to evaluate the algorithm in a validation set of 300 additional patients from twenty different SCT centers throughout the US. The algorithm worked perfectly, and the cumulative incidence of non-relapse mortality significantly increased as the GVHD score increased, and so the response rate to primary GVHD treatment decreased.

"This new scoring system will help identify patient who may not respond to standard treatments, and may require an experimental and more aggressive approach," said Dr. Ferrara. "And it will also help guide treatment for patients with lower-risk GVHD who may be over-treated. This will allow us to personalize treatment at the onset of the disease. Future algorithms will prove increasingly useful to develop precision medicine for all SCT patients."

In order to capitalize on this discovery, Dr. Ferrara has created the Mount Sinai Acute GVHD International Consortium (MAGIC) which consists of a group of ten SCT centers in the US and Europe who will collaborate to use this new scoring system to test new treatments for acute GVHD. Dr. Ferrara and colleagues have also written a protocol to treat high-risk GVHD that has been approved by the FDA.

###

Co-collaborators included University of Michigan, University of Regensburg, and the Blood and Marrow Clinical Trials Network.

The study was supported by grants from the National Cancer Institute; the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the Doris Duke Charitable Fund, the American Cancer Society, and the Judith Devries Fund.

Read more here:
Test predicts response to treatment for complication of leukemia stem cell treatment

stem cell therapy Nephrology Perspectives.Prof. Hussein Sheashaa 18.12.2014
stem cell therapy Nephrology Perspectives.Prof. Hussein Sheashaa 18.12.2014.

By: HusseinSheashaa

Read the original here:
stem cell therapy Nephrology Perspectives.Prof. Hussein Sheashaa 18.12.2014 - Video

Japanese Scientist Resigns in Stem Cell Scandal
A Japanese scientist who claimed a major breakthrough in stem cell research has resigned after the government lab where she worked could not replicate her results. Haruko Obokata said in a...

By: Mindreader

Read more:
Japanese Scientist Resigns in Stem Cell Scandal - Video

Portable Laminar Flow Hood for Stem Cell Analysis and Regenerative Medicine
Sentry Air Systems #39; ISO Class 5 Portable Clean Room Hood [Laminar Flow Hood] uses ductless technology and high quality HEPA filtration to create a positive p...

By: SentryAir

Read more:
Portable Laminar Flow Hood for Stem Cell Analysis and Regenerative Medicine - Video

The potential of SCs to replace dead or damaged cells in any tissue of the body heralds the advent of a new field of medicine that is delivering cures for diseases now thought to be untreatable

Stem cell therapy represents a promising avenue for the treatment of disorders like

Q1: What are stem cells? Answer: Stem cells are class of undifferentiated cells that are able to differentiate into specialized cell types .They have the unique properties of self renewal and differentiation. Differentiation property of stem cells help them to form another type of cell with more specialized function such as brain cell, red blood cell or muscle cell and also the entire organ. During the foetal development, cells divide, migrate, specialize and form the organ. After birth, stem cells are also present in bone marrow which can be used to treat various diseases.

Q2: Which disorders can be treated using Stem Cells? Answer: Currently stem cells are being used successfully to treat various (disorders) diseases like Cerebral palsy, Spinal Cord Injury, Traumatic brain injury, Paralysis, Brain Stroke Osteoarthritis, Autism etc. Apart from this, stem cells can be used to treat liver disorders and Diabetes.

Q3: How is Stem Cell Therapy carried out? Answer: Stem Cell therapy is a very simple and painless process.Mesenchymal stem cells are injected directly into the synivial fluid in the knee. The whole process is carried out very carefully under sterile conditions.

Read more from the original source:
Stem Cell Therapy in Pune | Stem Cell Treatment | Inamdar ...

Cytokines, Stem Cells and Skincare Lecture by Dr Dave Woynarowski
Discover the Latest Anti-Aging Skin Care Technologies from a Board-Certified Anti-Aging Doctor! with Dr. Dave Woynarowski http://rg-cell.com/dr-daves-talk-ammg-las-vegas-video/

By: RG-Cell Stem Cell Suport

The rest is here:
Cytokines, Stem Cells and Skincare Lecture by Dr Dave Woynarowski - Video

This treatment will only be allowed under carefully defined conditions, however, so that the outcomes can be carefully monitored to see if the treatment works and doesnt have any unexpected side-effects.

Stem cells can act as a repair system for the body.

Limbal stem cells are located in the eye at the border between the cornea the clear front part of the eye - and the sclera the white of the eye.

Physical or chemical burns can cause loss of these stem cells, resulting in limbal stem cell deficiency, LSCD, a condition that is estimated to affect about 3.3 out of 100,000 people in the European Union and around 650 people in Britain.

Symptoms include pain, sensitivity to light, inflammation, excessive blood vessel growth, clouding of the cornea, and eventually blindness.

In LSCD the limbal stem cells become so diminished that they eyes can no longer make new cells to repair damage.

The new treatment takes a small sample of the patients healthy cornea, removes the stem cells and grows them until there are sufficient numbers to put back into the eye. The cells themselves then repair the damage.

Moorfields Eye Hospital in London has successfully treated around 20 people with Holocar so far in trials.

Prof Chris Mason, from University College London, told the BBC: "This move would enable far more people to access it, you could now prescribe this."

The EMA decision to approve Holoclar will now be sent to the European Commission for market authorization. It will then be up to Nice to decide whether to approve the therapy for use on the NHS.

See the article here:
First stem-cell therapy approved for medical use in Europe

Defend Your Right to Affordable Regenerative Medicine
The FDA is trying to regulate how a doctor can use the cells and tissues from your own body. We have safely practiced Regenerative Medicine using PRP and stem cells for years, and have healed...

By: Dr. Noel Peterson

Here is the original post:
Defend Your Right to Affordable Regenerative Medicine - Video